Effect of Septimeb As a New Natural Extract on Severe Sepsis: A Randomized Clinical Trial

Overview

Journal Caspian J Intern Med

Specialty General Medicine

Date 2017 May 16

PMID 28503281

Citations 2

Authors

Alieh Pourdast

Maryam Sanaei

Sirous Jafari

Mostafa Mohammadi

Hossein Khalili

Gita Shafiee

Zeinab Ahadi

Mahsa Rostami

Saba Alizad

Ramin Heshmat

Minoo Mohraz

Affiliations

Soon will be listed here.

Abstract

Background: Septimeb as a herbal medicine has regulatory effects on inflammation. This study set to evaluate the effects of Septimeb among patients with sepsis on inflammatory biomarkers and survival rate.

Methods: In this randomized clinical trial, 51 patients with sepsis from the ICU and medical ward of Imam Khomeini Hospital were divided into two groups: Septimeb (n=25) and control group (n=26). In the control group, the patients received a standard treatment only for 7 days, while Septimeb group received Septimeb (6cc vial with 500cc serum glucose infusion 5% daily for one to two hours) plus standard treatment of sepsis for 7 days. Then, blood samples were analyzed. APACHE (Acute Physiologic and Chronic Health Evaluation), SOFA (Sequential Organ Failure Assessment), and GCS (Glasgow Coma Score) values were calculated daily.

Results: Treatment with Septimeb showed a significant decrease in SOFA value (1.54±0.83) compared to the control group (2.39±0.88) (P<0.001) and a significant increase in GCS value (14.46±0.88) compared to the control group (12.86±1.78) (P<0.001). Improvements of these values can confirm the potential of Septimeb in the reduction of severity of sepsis (P<0.05). There were significant decreases in lactate and blood sugar and WBC levels. In addition, inflammatory factors such as ESR (Septimeb group: 52.07±34.80, control group: 51.75±42.10, P=0.98) and CRP (Septimeb group: 48.86±23.21, control group: 49.93±36.22, P=0.92) decreased, but did not show a significant reduction.

Conclusion: Septimeb has positive effects on reduction of the severity of sepsis which leads to reduction of patients' mortality rates.

Citing Articles

3,4-Dihydroxyphenylethanol ameliorates lipopolysaccharide-induced septic cardiac injury in a murine model.

Zhang L, Wen K, Zhang Z, Ma C, Zheng N Open Life Sci. 2022; 16(1):1313-1320.

PMID: 35005242 PMC: 8691377. DOI: 10.1515/biol-2021-0125.

In vitro cultivation of tansy (Tanacetum vulgare L.): a tool for the production of potent pharmaceutical agents.

Devrnja N, Krstic-Milosevic D, Janosevic D, Tesevic V, Vinterhalter B, Savic J Protoplasma. 2020; 258(3):587-599.

PMID: 33244630 PMC: 7691073. DOI: 10.1007/s00709-020-01588-9.

References

Mikkelsen M, Miltiades A, Gaieski D, Goyal M, Fuchs B, Shah C . Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009; 37(5):1670-7. DOI: 10.1097/CCM.0b013e31819fcf68. View

Friedman G, Silva E, Vincent J . Has the mortality of septic shock changed with time. Crit Care Med. 1999; 26(12):2078-86. DOI: 10.1097/00003246-199812000-00045. View

Pradillo J, Denes A, Greenhalgh A, Boutin H, Drake C, McColl B . Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab. 2012; 32(9):1810-9. PMC: 3434631. DOI: 10.1038/jcbfm.2012.101. View

Moreno R, Metnitz B, Adler L, Hoechtl A, Bauer P, Metnitz P . Sepsis mortality prediction based on predisposition, infection and response. Intensive Care Med. 2007; 34(3):496-504. DOI: 10.1007/s00134-007-0943-1. View

Riedemann N, Guo R, Ward P . Novel strategies for the treatment of sepsis. Nat Med. 2003; 9(5):517-24. DOI: 10.1038/nm0503-517. View

de Mendonca A, Vincent J, Suter P, Moreno R, Dearden N, Antonelli M . Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000; 26(7):915-21. DOI: 10.1007/s001340051281. View

Douzinas E, Tsidemiadou P, Pitaridis M, Andrianakis I, Katsouyanni K, Sfyras D . The regional production of cytokines and lactate in sepsis-related multiple organ failure. Am J Respir Crit Care Med. 1997; 155(1):53-9. DOI: 10.1164/ajrccm.155.1.9001289. View

Knaus W, Draper E, Wagner D, Zimmerman J . APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10):818-29. View

Lambertsen K, Biber K, Finsen B . Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012; 32(9):1677-98. PMC: 3434626. DOI: 10.1038/jcbfm.2012.88. View

10.

Sands K, Bates D, Lanken P, Graman P, Hibberd P, Kahn K . Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997; 278(3):234-40. View

11.

James J, Luchette F, McCarter F, Fischer J . Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet. 1999; 354(9177):505-8. DOI: 10.1016/S0140-6736(98)91132-1. View

12.

Sheldon J, Riches P, Gooding R, Soni N, Hobbs J . C-reactive protein and its cytokine mediators in intensive-care patients. Clin Chem. 1993; 39(1):147-50. View

13.

Mohseni-Salehi-Monfared S, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M . Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes. Arch Med Sci. 2012; 6(5):663-9. PMC: 3298332. DOI: 10.5114/aoms.2010.17078. View

14.

Paydary K, Emamzadeh-Fard S, Khorshid H, Kamali K, SeyedAlinaghi S, Mohraz M . Safety and efficacy of Setarud (IMOD TM ) among people living with HIV/AIDS: a review. Recent Pat Antiinfect Drug Discov. 2012; 7(1):66-72. DOI: 10.2174/157489112799829756. View

15.

Hamishehkar H, Beigmohammadi M, Abdollahi M, Ahmadi A, Mahmoodpour A, Mirjalili M . Identification of enhanced cytokine generation following sepsis. Dream of magic bullet for mortality prediction and therapeutic evaluation. Daru. 2012; 18(3):155-62. PMC: 3304360. View

16.

Farhoudi M, Najafi-Nesheli M, Hashemilar M, Mahmoodpoor A, Sharifipour E, Baradaran B . Effect of IMOD™ on the inflammatory process after acute ischemic stroke: a randomized clinical trial. Daru. 2013; 21(1):26. PMC: 3620936. DOI: 10.1186/2008-2231-21-26. View

17.

Cai B, Deitch E, Ulloa L . Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm. 2010; 2010:642462. PMC: 2902015. DOI: 10.1155/2010/642462. View

18.

Baghaei A, Esmaily H, Abdolghaffari A, Baeeri M, Gharibdoost F, Abdollahi M . Efficacy of Setarud (IMod), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab. Indian J Biochem Biophys. 2010; 47(4):219-26. View

19.

Look M, Rockstroh J, Rao G, Barton S, Lemoch H, Kaiser R . Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study. Eur J Clin Invest. 1998; 28(5):389-97. DOI: 10.1046/j.1365-2362.1998.00301.x. View

20.

Eslami K, Mahmoodpoor A, Ahmadi A, Abdollahi M, Kamali K, Mousavi S . Positive effect of septimeb™ on mortality rate in severe sepsis: a novel non antibiotic strategy. Daru. 2013; 20(1):40. PMC: 3555989. DOI: 10.1186/2008-2231-20-40. View